• SVP Century Therapeutics

    Built research organization from 3 team members to over 60, including core capabilities in cell engineering, protein engineering, iPSC biology, in vitro and in vivo pharmacology. Contributed to the regulatory filing of the first ever precision engineered iPCS-derived cell therapy to enter into clinical trials.

  • Director and head of gene and cell therapy-JNJ

    Established the first ever gene and cell therapy discovery group at JNJ. Established key partnerships and internal capabilities to modify T cells for therapeutic programs and AAV gene therapies.

  • Director-target discovery and antibody engineering-JNJ

    Lead for a team that validated novel targets for multiple therapeutic areas that resulted in the start of many antibody discovery programs within the antibody discovery group. Part of the leadership team that brought novel antibody targeting technologies into Janssen R&D, including bispecific tehcnologies.

Michael Naso, PhD

Michael Naso has worked for more than 25 years in pharma and biotech organizations toward the discovery and advancement into early development innovative therapeutics including antibodies, bispecific antibodies, cell and gene therapies.  Michael contributed to the successful approval and marketing of REMICADE, SIMPONI, STELARA, TREMFYA, and numerous preclinical programs at Centocor and Janssen.  Most recently, he helped found Century Therapeutics and built the research organization that brought the first ever multiple precision-engineered, iPSC-derived cell therapy into the clinic for the treatment of lymphoma and autoimmunity.  Michael has deep expertise in antibody discovery, protein engineering, gene editing, cell therapy, iPSCs, regulatory submissions, and patent filings.  He has also served as an expert witness in legal matters.